ArticleNeurocritical care2026
Associations of Vasopressin and Corticosteroid Therapy with Organ Yield in Brain-Dead Donors: A Multicenter Cohort Study in Japan.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptimizing intensive care management of cases in which donors are brain-dead is essential to maximize the number of transplantable organs. Hormone replacement therapy, including vasopressin and corticosteroids, is widely used to stabilize donor hemodynamics; however, its impact on organ procurement remains uncertain. This study aimed to evaluate the association between vasopressin, corticosteroid therapy, and organ yield among donors who were brain-dead.
methodsWe conducted a multicenter, retrospective analysis of the Japan Comprehensive Process for End-of-Life Care and Organ Donation after Brain Death (J-RESPECT) cohort, including data from 16 institutions in Japan between 17 July 2010 and 31 December 2023. Donors were classified into high-yield (≥ 6 organs) and low-yield (≤ 5 organs) groups based on the median number of organs procured. Vasopressin and corticosteroid doses were categorized, and generalized estimating equations were applied to assess associations with high-yield procurement and organ-specific donation, adjusting for donor characteristics and clinical variables.
resultsThe median donor age was 47 years, 92 donors (45.1%) were female, and the median time from admission to procurement was 10 days. Donors in the high-yield group (n = 125) had a median of seven organs procured compared with four in the low-yield group (n = 79). After adjustment for donor characteristics, concurrent catecholamine support, and the number of organs requested by the family, low-dose methylprednisolone (< 15 mg/kg/day) was associated with higher odds of high-yield organ procurement (odds ratios, 2.86; 95% confidence intervals, 1.45-5.63), whereas vasopressin dose was not. In exploratory organ-specific analyses, high-dose methylprednisolone (≥ 15 mg/kg/day) was associated with left lung procurement, whereas no consistent associations were observed for other organs.
conclusionsIn this multicenter cohort study, low-dose methylprednisolone, but not vasopressin dose, was associated with higher organ yield after adjustment for important clinical confounders. These findings should be interpreted cautiously and warrant confirmation in prospective studies to better define the role of individual hormone replacement therapies in donor case management.
Indexed as
Identifiers
42754809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.